Abstract 17499: Addition of Myocardial Parameters to the Diagnosis of Stage B Heart Failure

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Tom Marwick ◽  
Wojciech Kosmala ◽  
Christine Jellis

Introduction: Stage B heart failure (BHF, asymptomatic structural heart disease) is diagnosed in the presence of myocardial scar or impaired LVEF. However, the insensitivity of LVEF may lead to under-recognition of BHF in non-ischemic heart disease. This may be important, as BHF may precede the onset of HF symptoms, and necessitates the initiation of treatment. We sought the implications of using additional LV assessment to identify BHF in pts at risk of HF (stage A HF, AHF). Methods: We studied 510 asymptomatic pts (age 58±12yrs) with AHF (diabetes, hypertension or obesity), but no history of ischemic heart disease and a normal stress echo. All pts underwent echocardiography (including assessment of strain and diastolic dysfunction) and cardiopulmonary exercise testing. Results: BHF was defined as the presence of at least one of; reduced LV longitudinal strain (<18%), increased LV filling pressure (E/e’>13) or moderate-to-severe LV hypertrophy (LV mass index ≥109 g/m 2 in women and 132 g/m 2 in men) in 243 patients (47%). Reduced exercise capacity (peakVO 2 and METS) was identified in BHF compared with other AHF (Table). Using this definition, BHF was associated with lower peak VO 2 (β=-0.20, p<0.00001) and METS (β=-0.21, p<0.0001), independent of higher BMI, insulin resistance, older patient age, male sex and treatment with beta-blockers. Conclusions: LV hypertrophy, elevated LV filling pressure elevation and abnormal myocardial deformation independently contribute to lower exercise capacity in pts at risk of HF. Given the association of exercise capacity with outcome, these factors should be considered grounds for the diagnosis of BHF.

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
N Swiatoniowska-Lonc ◽  
E Jaciow ◽  
J Polanski ◽  
B Jankowska-Polanska

Abstract Funding Acknowledgements Type of funding sources: None. Background. Falls among the elderly are a major cause of injury, significant disability and premature death. Hypotension is a potential risk factor for falls in older adults, especially patients with hypertension (HTN) taking antihypertensive drugs. Furthermore, the cardiovascular benefit of treatment of hypertension in older patients is clear, findings from observational studies have raised concerns that antihypertensive therapies in the elderly might also induce adverse effects, including injurious falls.  In spite of the large number of issues related to this topic, the analysis of the causes of falls is insufficient. The aim of the study was to assess the frequency of falls and the impact of selected variables on the occurrence of risk of falls among patients with HTN. Material and methods. 100 patients, including 55 women, with HTN (mean age 69.4 ± 3.29 years) were enrolled into the study. The Tinetti test was used to assess the risk of falls. Sociodemographic and clinical data were obtained from the hospital register. Results. 89% of patients had a high risk of falls and 11% were prone to falls. The average number of falls during the last year in the study group was 1.86 ± 2.82 and in 30% of cases the fall was the cause of hospitalization. Single-factor analysis of the influence of selected variables on the risk of falls showed that higher values of SBP (-0.27; p = 0.007), DBP (-0.279; p = 0.005) and younger age of patients decrease the risk of falls (-0.273; p = 0.006). The linear regression model showed that independent predictors increasing the risk of falling are: use of diuretics (β=4.192; p &lt; 0.001), co-occurrence of ischemic heart disease (β=4.669; p = 0. 007) and co-occurrence of heart failure (β=3.494; p = 0.016), and predictors reducing the risk of falling patients with hypertension are: the use of beta-blockers (β= -4.033; p = 0.013) and higher DBP value (β= -0.123; p = 0.016). Conclusions. Patients with HTN have a high risk of falling. Independent determinants increasing the risk of falling patients with HTN are the use of diuretics and the co-occurrence of ischemic heart disease or heart failure, while beta-blockers and a higher DBP value are factors reducing the risk of falling. Fall risk assessment and implementation of fall prevention should be carried out in everyday practice.


2021 ◽  
pp. 53-57
Author(s):  
Sofiia Dolinska ◽  
Viktoriia Potaskalova ◽  
Mykola Khaitovych

Due to the development of the pharmaceutical industry, today there are a large number of drugs with similar properties and efficacy, but little-studied pharmacodynamics and pharmacokinetics. There fore many medicines are prescribed more often and in larger quantities than necessary. That is why patients and doctors often face the problem of polypharmacy in various fields of medicine including cardiology. The paper presents the results of the analysis of 249 case histories of inpatients with cardiac profile. All patients with underlying cardiac pathology (arterial hypertension, ischemic heart disease) had concomitant diseases. Patients with arterial hypertension had other concomitant diseases, most often gout, diseases of the digestive system, anemia. Chronic heart failure was found in the majority of patients with arterial hypertension, ischemic heart disease, chronic rheumatic heart disease. We have determined which pharmacological groups of drugs are prescribed to patients with arterial hypertension or chronic heart failure and concomitant diseases: more than 60 % of patients are prescribed drugs that are unsuitable for their condition. We analyzed and compared treatment standards in Ukraine and the world and carried out that doctors in Ukraine use modern and effective methods of treatment. The risks of prescribing a large number of drugs to patients are analyzed and the risks of dangerous drug interactions that can threaten the life or health of the patient are identified. In particular, in the treatment of cardiac patients, doctors used combinations of calcium antagonists and beta-blockers, NSAIDs and antithrombotic drugs, corticosteroids and antibacterial drugs of the fluoroquinolone group, ACE inhibitors and potassium-preserving diuretics, antiarrhythmic drugs and highly active diuretics, etc. We compared medicinal prescriptions for the treatment of cardiovascular diseases with an interval of 10 years and revealed that in 2008 the therapy often did not comply with the international and Ukrainian treatment protocols, however, in 2018, unwanted drug interactions were found 4 times less often. That reflects the trend of doctors’ awareness of pharmacology and evidence-based medicine.


2016 ◽  
Vol 72 (1) ◽  
Author(s):  
Alberto Genovesi Ebert ◽  
Furio Colivicchi ◽  
Marco Malvezzi Caracciolo ◽  
Carmine Riccio

The prevention of symptomatic heart failure represents the treatment of patients in the A and B stages of AHA/ACC heart failure classification. Stage A refers to patients without structural heart disease but at risk to develop chronic heart failure. The major risk factors in stage A are hypertension, diabetes, atherosclerosis, family history of coronary artery disease and history of cardiotoxic drug use. In this stage, blockers hypertension is the primary area in which beta blockers may be useful. Beta blockers seem not to be superior to other medication in reducing the development of heart failure due to hypertension. Stage B heart failure refers to structural heart disease but without symptoms of heart failure. This includes patients with asymptomatic valvular disease, asymptomatic left ventricular (LV) dysfunction, previous myocardial infarction with or without LV dysfunction. In asymptomatic valvular disease no data are available on the efficacy of beta blockers to prevent heart failure. In asymptomatic LV dysfunction only few asymptomatic patients have been enrolled in the trials which tested beta blockers. NYHA I patients were barely 228 in the MDC, MERIT and ANZ trials altogether. The REVERT trial was the only trial focusing on NYHA I patients with LV ejection fraction less than 40%. Metoprolol extended release on top of ACE inhibitors ameliorated LV systolic volume and ejection fraction. A post hoc analysis of the SOLVD Prevention trial demonstrated that beta blockers reduced death and development of heart failure. Similar results were reported in post MI patients in a post hoc analysis of the SAVE trial (Asymptomatic LV failure post myocardial infarction). In the CAPRICORN trial about 65% of the patients were not taking diuretics and then could be considered asymptomatic. The study revealed a reduction in mortality and a non-significant trend toward reduction of death and hospital admission for heart failure. Conclusions: beta blockers are not specifically indicated in stage A heart failure. On the contrary, in most of the stage B patients, and particularly after MI, beta blockers are indicated to reduce mortality and, probably, also the progression toward symptomatic heart failure.


2016 ◽  
Vol 8 (4) ◽  
pp. 314 ◽  
Author(s):  
С.А. Ковалёв ◽  
В. Н. Белов ◽  
О.А. Осипова

Актуальность У больных с многососудистым поражение коронарных артерий и ствола левой коронарной артерии коронарное шунтирование (КШ) является эффективным методом лечения. В тоже время у ряда пациентов в различные сроки после успешно проведенной хирургической реваскуляризации миокарда развивается клинически выраженная хроническая сердечная недостаточность (ХСН).Материалы и методы Обследовано 32 пациента с ишемической болезнью сердца и ХСН III/IV функционального класса (ФК) по NYHA, манифестирующей через 8±2 года после КШ. Фракция выброса левого желудочка после хирургической реваскуляризации миокарда при манифестации ХСН составила 34,1± 4%. 25 (78%) пациентам, включенным в исследование были выполнены коронаро-, шунтография. После рассмотрения кардиологическим консилиумом результатов обследования данным больным повторная реваскуляризация миокарда была не показана. В связи с сохраняющейся низкой переносимостью физических нагрузок пациентам дополнительно к базовой терапии ХСН был назначен экзогенный фосфокреатин (Неотон) внутривенно капельно в суточной дозе 3±0,5 гр. на 12±2 дня. Доза экзогенного фосфокреатина выбиралась в зависимости от степени ФК сердечной недостаточности. Результаты и их обсуждение Добавление фосфокреатина к стандартной терапии привело к улучшению ФК ХСН у 17 из 32 (53%) пациентов, включенных в исследование. У 30% больных, ответивших на терапию фосфокреатином (Неотон), повышение переносимости физической нагрузке наблюдалось после 1 курса терапии, у 70% пациентов - после 2 курса лечения препаратом. На фоне лечения фосфокреатином (Неотон) в целом по группе отмечалось достоверное повышение ФК ХСН с 3,4± 0,3 до 2,7± 0,6 (р <0,001). Наибольшая эффективность препарата была отмечена у пациентов с III ФК ХСН. Побочные эффекты терапии наблюдались у 3 (9%) пациентов и проявлялись в виде развитие умеренной гипотонии в основном при введении более 4 гр. препарата, которая купировалась снижение скорости инфузии фосфокреатина (Неотон).Вывод Лечение экзогенным фософокреатином (Неотон) больных с III/IV ФК ХСН после проведенного КШ позволяет более чем у 50% пациентов уменьшить клинические проявления сердечной недостаточности и повысить толерантность к физическим нагрузкам при хорошей переносимости терапии. Рекомендуется включение данного препарата в комплексное лечение ХСН у больных ишемической болезнью сердца (ИБС) при невозможности повторной реваскуляризации миокар


Sign in / Sign up

Export Citation Format

Share Document